Home › Cases › Elective Cardioversion of Persistent AF
Atrial Fibrillation
Elective Cardioversion of Persistent AF
6 questions
Question 1 · Anticoagulation before cardioversion
Correct answer: ≥3 weeks therapeutic anticoagulation, or TOE-guided on anticoagulation
Why
AF >48 h or unknown onset: ≥3 weeks therapeutic anticoagulation before cardioversion, or TOE-guided cardioversion on anticoagulation. Continue ≥4 weeks after, then by CHA₂DS₂-VASc.
Key point
3 weeks therapeutic anticoagulation or anticoagulated TOE; ≥4 weeks after.
Question 2 · TOE-guided cardioversion
Correct answer: TOE on therapeutic anticoagulation; cardiovert if no thrombus; anticoagulate ≥4 weeks after
Why
AF >48 h or unknown onset: ≥3 weeks therapeutic anticoagulation before cardioversion, or TOE-guided cardioversion on anticoagulation. Continue ≥4 weeks after, then by CHA₂DS₂-VASc. Atrial stunning: mechanical recovery can lag behind electrical sinus rhythm.
Key point
3 weeks therapeutic anticoagulation or anticoagulated TOE; ≥4 weeks after.
Question 3 · DC cardioversion procedure
Correct answer: R-wave synchronised shock at maximum output; careful sedation/anaesthesia, A-P or A-L pads
Why
Synchronised shock at maximum output. Synchronise to the R wave to avoid a T-wave shock causing VF. A-P or A-L pads are acceptable. Conscious patients need careful sedation or anaesthesia, monitoring, oxygen and immediate resuscitation equipment.
Key point
AF: synchronised shock at maximum output. A-P or A-L pads. Careful sedation/anaesthesia with monitoring and rescue equipment.
Question 4 · Post-cardioversion anticoagulation
Correct answer: No — continue anticoagulation minimum 4 weeks post-CV (atrial stunning), then long-term based on CHA2DS2-VASc
Why
Post-cardioversion: 4 weeks anticoagulation mandatory regardless of successful cardioversion (atrial stunning = mechanical dysfunction despite electrical sinus rhythm). Long-term anticoagulation continues if CHA2DS2-VASc ≥2 (men) because AF frequently recurs silently.
Key point
Anticoagulate ≥4 weeks post-DCCV (atrial stunning). Long-term if CHA2DS2-VASc ≥2. Never stop immediately.
Question 5 · Rhythm maintenance
Correct answer: Anti-arrhythmic drugs (flecainide if no structural heart disease, amiodarone if structural disease) or referral for catheter ablation
Why
Rhythm maintenance: anti-arrhythmic drugs (flecainide, dronedarone for paroxysmal; amiodarone for structural disease). Catheter ablation (pulmonary vein isolation) increasingly first-line for symptomatic persistent AF in fit patients — superior to drugs for maintaining SR long-term.
Key point
Recurrent symptomatic AF: anti-arrhythmic drugs or catheter ablation. Ablation increasingly preferred first-line.
Question 6 · Rate vs rhythm
Correct answer: Rate control is equivalent to rhythm control for most AF patients (AFFIRM trial). Acceptable if asymptomatic
Why
AFFIRM trial: rate control equivalent to rhythm control for mortality in AF. Rate control reasonable first-line for asymptomatic or mildly symptomatic AF. Rhythm control preferred if: young, symptomatic, HF secondary to AF, or patient preference.
Key point
Asymptomatic AF: rate control = rhythm control for mortality (AFFIRM). Symptom-driven decision.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.